World Journal of Urology

, Volume 36, Issue 4, pp 681–682 | Cite as

No convincing evidence on differences in metabolic effects of medical and surgical castration in the treatment of prostate cancer

  • Peter B. Østergren
  • Tobias Wirenfeldt Klausen
  • Mikkel Fode
Letter to the Editor

Keywords

Androgen deprivation therapy Castration Metabolic syndrome Prostatic neoplasms 

Notes

Author contributions

PBØ: Project development, Data management, Data analysis, Manuscript editing. TWK: Data management, Data analysis, Manuscript editing. MF: Project development, Data management, Data analysis, Manuscript writing.

Compliance with ethical standards

Conflict of interest

This is a letter to the editor not directly involving human participants or animals. The authors would like to declare the following conflicts of interest: Peter B. Østergren has received honorarium as a speaker for Astellas and Ferring. Mikkel Fode has received honorarium as a speaker and advisory board member for Astellas. Tobias Wirenfeldt Klausen has no conflicts of interest.

References

  1. 1.
    Vargas A, Machado RD, Filho DI, Paiva CE, Dos Reis RB, Tobias-Machado M, Faria EF (2016) LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer. World J Urol 34(12):1621–1628CrossRefPubMedGoogle Scholar
  2. 2.
    Oka H, Negoro H, Sugino Y, Iwamura H, Moroi S, Kawakita M (2003) Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment. Hinyokika Kiyo 49(9):521–525PubMedGoogle Scholar
  3. 3.
    Ostergren PB, Kistorp C, Fode M, Henderson J, Bennedbaek FN, Faber J, Sonksen J (2016) Luteinizing hormone-releasing hormone agonists are superior to subcapsular orchiectomy in lowering testosterone levels of men with prostate cancer: results from a randomized clinical trial. J Urol. doi: 10.1016/j.juro.2016.12.003 (Epub ahead of print) PubMedGoogle Scholar
  4. 4.
    Keating NL, O’Malley AJ, Freedland SJ, Smith MR (2010) Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 102(1):39–46CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van HM (2015) Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33(11):1243–1251CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Department of UrologyHerlev and Gentofte HospitalHerlevDenmark
  2. 2.Department of HaematologyHerlev and Gentofte HospitalHerlevDenmark
  3. 3.Department of UrologyZealand University HospitalRoskildeDenmark

Personalised recommendations